Organogenesis Holdings Inc. Class A Common Stock (ORGO)
Stock · NASDAQ · Health Care
$0.9998as of 10/16/2026
Price chart
Active signals
ORGO Signal Track Record
How signals performed across all stocks →What ORGO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | +0.4% | 51% | October 5, 2026 |
| Bollinger Band Breakout | 23 | -11.8% | 35% | July 16, 2026 |
| Bollinger Band BreakdownActive now | 20 | +1.5% | 55% | September 11, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +11.2% | 58% | January 5, 2026 |
| Any 20-session window (baseline) | -3.0% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ORGO
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 854
- Website
- investors.organogenesis.com
Fundamentals
- 1-day range
- $1.1$1.15
- Market cap
- $310.11M
- P/E (trailing)
- 84.95
- P/E (forward)
- -3.58
- EPS (trailing)
- $-0.69
- Dividend yield
- —
- Beta
- 1.44
- Avg. volume
- 745.7K
How Organogenesis Holdings Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Organogenesis Holdings Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- ORGOOrganogenesis Holdings Inc. Class A Common Stock$1▼ 9.91%Market cap $310.11MP/E 84.95$1.13$7.08
- VNDAVanda Pharmaceuticals Inc. Common Stock$4.03▼ 4.95%Market cap $307.59MP/E —$4.27$9.94
- IRDOpus Genetics Inc. Common Stock$3.84▼ 5.19%Market cap $307.14MP/E —$1.7$7.07
- AMRNAmarin Corporation plc$11.32▼ 2.16%Market cap $301.21MP/E —$11.34$20.9
- GALTGalectin Therapeutics Inc. Common Stock$3.62▼ 2.43%Market cap $324.74MP/E —$2.03$7.13
- FHTXFoghorn Therapeutics Inc. Common Stock$1.85▼ 2.12%Market cap $327.04MP/E —$1.79$7.61
- IMRXImmuneering Corporation Class A Common Stock$3.59▼ 1.37%Market cap $288.55MP/E —$3.6$8.48
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ORGO Organogenesis Holdings Inc. Class A Common Stock | $310.11M | 84.95 | $1 | ▼ 9.91% | $1.13$7.08 |
| VNDA Vanda Pharmaceuticals Inc. Common Stock | $307.59M | — | $4.03 | ▼ 4.95% | $4.27$9.94 |
| IRD Opus Genetics Inc. Common Stock | $307.14M | — | $3.84 | ▼ 5.19% | $1.7$7.07 |
| AMRN Amarin Corporation plc | $301.21M | — | $11.32 | ▼ 2.16% | $11.34$20.9 |
| GALT Galectin Therapeutics Inc. Common Stock | $324.74M | — | $3.62 | ▼ 2.43% | $2.03$7.13 |
| FHTX Foghorn Therapeutics Inc. Common Stock | $327.04M | — | $1.85 | ▼ 2.12% | $1.79$7.61 |
| IMRX Immuneering Corporation Class A Common Stock | $288.55M | — | $3.59 | ▼ 1.37% | $3.6$8.48 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Institutional Ownership
March 31, 2026
- Total shares held
- 59.52M
- Total value held
- $135.27M
- Institutional holders
- 116
- Unknown11.62M
- Unknown10.09M
- Unknown4.90M
- Unknown3.50M
- Unknown2.90M
- Unknown2.89M
- Unknown2.30M
- Unknown1.97M
- Unknown1.78M
- Unknown1.71M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Organogenesis publishes positive PREPARE trial results for PuraPly AM
Organogenesis has released peer-reviewed results from the PREPARE trial, showing that PuraPly AM provided clinical benefit for hard-to-heal diabetic foot ulcers. The company also confirmed it will report its third-quarter fiscal 2026 financial results on November 5, 2026. These updates provide new data points for investors monitoring the firm's product performance ahead of the upcoming earnings release.
Organogenesis publishes positive PREPARE trial results for PuraPly AM. Organogenesis has released peer-reviewed results from the PREPARE trial, showing that PuraPly AM provided clinical benefit for hard-to-heal diabetic foot ulcers. The company also confirmed it will report its third-quarter fiscal 2026 financial results on November 5, 2026. These updates provide new data points for investors monitoring the firm's product performance ahead of the upcoming earnings release.